Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

RECEIVED. SECRETARY OF THE S

05 FEB 14 PM11

## **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

1. Registrant Name		
Canfield & Associates, Inc.		
2. Registrant Address	· · · · · · · · · · · · · · · · · · ·	Suite 625 DC 20004
3. Principal Place of Business (if different	ent from line 2)	
City Same	State/Zip (or Country)	
4. Contact Name  Anne Canfield	Telephone E-ma	5. Senate ID # 7997-00125
7. Client Name  Self Pfizer, Inc.		6. House ID# 3359-2009
INCOME OR EXPEN		
12. Lobbying INCOME relating to lobbying a period was:	_	13. Organizations  EXPENSES relating to lobbying activities for this reperiod were:
Less than \$10,000		Less than \$10,000
\$10,000 or more 🔀 >> \$	\$20,000.00 Income (nearest \$20,000)	\$10,000 or more
		Expenses (nearest \$
Provide a good faith estimate, ro \$20,000 of all lobbying related in (including all payments to the re- for lobbying activities on behalf	ncome from the client gistrant by any other entity	14. REPORTING METHOD. Check box to indica accounting method. See instructions for description of Method A. Reporting amounts using LDA defin  Method B. Reporting amounts under section 600

Filing #b96edc8c-9409-4b89-8eeb-4f05270bf199 - Page 1 of 6

Data 2/14/2005

ыднише	•	Daw	
Printed Name and Title	Anne Canfield - President		Pa

## 00000061991

Reg	istrant Name:	Canfield & Associates, Inc.			
Clie	nt Name:	Pfizer, Inc.			
enga	aged in lobbyir		to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide l.		
15.	General issue	area code HCR (one per page)			
16.	P.L. 108-173, Medicare Prescription Drug and Modernization Act of 2003, Issues related to delivery of operacription drugs to Medicare beneficiaries S. 1125, Fairness in Asbestos Injury Resolution Act of 2003, S. 2328, Pharmaceutical Market Access and Drug Safety Act of 2004, Issues related to the importation of drugs Issues related to amending the Medicare Prescription Drug and Modernization Act of 2003 (P.L. 108-17 "noninterferance" language and to authorize the Secretary of HHS to negotiate drug prices for the Part prescription drug benefit.				
17.	Department Executive O	Congress and Federal agencies contacted of Health & Human Services ffice of the President presentatives	☐ Check if None		
18.	Name of each	n individual who acted as a lobbyist in this	issue area		
	Name		Covered Official Position (if applicable)		
	Blauwet, Ro	ger			
	Canfield, Ar	nne			
	Frederick, E	rin			
19.	Interest of ea	ch foreign entity in the specific issues liste	d on line 16 above 🔀 Check if None		

Thata 2/14/2005

0:-----

Signature		Date	 
<del>-</del>			
Printed Name and Title	Anne Canfield - President	<u> </u>	 P

## 00000061992

Regi	strant Name:	Canfield & Associates, Inc.	
Clie	nt Name:	Pfizer, Inc.	
enga	iged in lobbyin		to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide l.
15. General issue area code <u>TAX</u> (one per page)			
16.	Specific Lobb P.L. 108-357		ssues related to repatriation of foreign source income.
17.	` '	Congress and Federal agencies contacted f Representatives	☐ Check if None
18.	Name of each	n individual who acted as a lobbyist in this	issue area
	Name		Covered Official Position (if applicable)
	Blauwet, Ro	ger	
	Canfield, An	ne	
	Frederick, E	rin	
	-	•	
10	Intornat - F	ah famian antity in the analisis issues Vice	d on line 16 above 🔀 Check if None
17.	interest of ea	ch foreign entity in the specific issues liste	d on line 16 above 🔀 Check if None

Data 2/14/2005

Cianatur

Signature		 Date	 
Printed Name and Title	Anne Canfield - President		 Pi